Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay

Cancer Genetics

Volumn 206, Issue 4, 2013, Pages 130-134

  Burchard, Paul R ^a,b   Malhotra, Saurabh ^a,b   Kaur, Prabhjot ^a,b   Tsongalis, Gregory J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

B lymphocytes; FCGR3a; Polymerase chain reaction; Rituximab; TaqMan allelic discrimination assay

Indexed keywords

CD16 ANTIGEN;

ARTICLE; CD16 GENE; CONTROLLED STUDY; DNA EXTRACTION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPING TECHNIQUE; HIGH RESOLUTION MELTING ANALYSIS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TURNAROUND TIME; WILD TYPE;

GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IGG;

EID: 84878955381     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2013.03.002     Document Type: Article

References (32)

1. Borker A., Choudhary N. Rituximab. Indian Pediatr 2011, 48:627-632.
2. Fanger M.W., Shen L., Graziano R.F., et al. Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989, 10:92-99.
3. Kastbom A., Ahmadi A., Söderkvist P., et al. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology (Oxford) 2005, 44:1294-1298.
4. Nieto A., Cáliz R., Pascual M., et al. Involvement of Fc gamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000, 43:735-739.
5. Nockher W.A., Scherberich J.E. Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun 1998, 66:2782-2790.
6. Ozturk C., Aksu G., Berdeli A., et al. Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases. Clin Exp Med 2006, 6:27-32.
7. Tanaka Y., Suzuki Y., Tsuge T., et al. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2005, 20:2439-2445.
8. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002, 2:580-592.
9. Chen J.-Y., Wang C.-M., Wu J.-M., et al. Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin Exp Immunol 2006, 144:10-16.
10. Dimou N.L., Nikolopoulos G.K., Hamodrakas S.J., et al. Fcgamma receptor polymorphisms and their association with periodontal disease: a meta-analysis. JClin Periodontol 2010, 37:255-265.
11. Hans V.M., Mehta D.S. Genetic polymorphism of Fcγ-receptors IIa, IIIa and IIIb in South Indian patients with generalized aggressive periodontitis. JOral Sci 2011, 53:467-474.
12. Huang Y., Yin H., Wang J., et al. The significant increase of FcγRIIIA (CD16), a sensitive marker, in patients with coronary heart disease. Gene 2012, 504:284-287.
13. Deo Y.M., Graziano R.F., Repp R., et al. Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today 1997, 18:127-135.
14. Wallace P.K., Howell A.L., Fanger M.W. Role of Fc gamma receptors in cancer and infectious disease. JLeukoc Biol 1994, 5:816-826.
15. Braendstrup P., Bjerrum O.W., Nielsen O.J., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005, 78:275-280.
16. Taylor R.P., Lindorfer M.A. Antigenic modulation and rituximab resistance. Semin Hematol 2010, 4:124-132.
17. Toumeh A., Josh N., Narwal R., et al. Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. Am J Ther 2012, [Epub ahead of print].
18. Rüfer A., Brodmann D., Gregor M., et al. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 2007, 137:518-524.
19. Papaioannou D., Rafia R., Rathbone J., et al. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess 2012, 16:1-253.
20. Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
21. Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63:803-843.
22. Jazirehi A.R., Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:2121-2143.
23. Weiner G.J. Rituximab: mechanism of action. Seminars in Hematology 2010, 47:115-123.
24. Lee L., Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol 2012, 2012:984-986.
25. Pamuk G.E., Donmez S., Turgut B., et al. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005, 78:81.
26. Dhand S., Bahrain H. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature. Cancer Invest 2008, 26:913-915.
27. Tesfa D., Ajeganova S., Hägglund H., et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011, 63:2209-2214.
28. Tesfa D., Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011, 4:619-625.
29. Child N., O'Carroll M., Berkahn L. Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. Intern Med J 2012, 42:e12-e14.
30. Akyurek N., Uner A., Benekli M., et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012, 118:4173-4183.
31. Kastbom A., Cöster L., Arlestig L., et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open 2012, 2:1-5.
32. Ruyssen-Witrand A., Rouanet S., Combe B., et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012, 71:875-877.